[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Lancet Oncol. (2018) S. Nilsson et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, ...
Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2020; 10:9364–77. doi:https://doi.org/10.7150/thno.48107. Available from https://www.thno.org/v10p9364.htm. CS Bal S Ballal MP Yadav 2021 Long-term ...
Recently, clinical studies using 225Ac-labeled PSMA-ligands ([225Ac]Ac-PSMA-617 or [225Ac]Ac-PSMA-I&T) have reported remarkable therapeutic results [23,24,25,26,27,28,29,30]. However, the stronger radiobiological effect of alpha particles also has implications to the organs at risk. ...
In this review, we have summarized and discussed the clinical data of 177Lu-PSMA and 225Ac-PSMA RNT in patients with mCRPC. Keywords: actinium-225; lutetium-177; prostate-specific membrane antigen (PSMA); metastatic castration-resistant prostate cancer (mCRPC); radionuclide therapy (RNT)...